Treatment of medullary thyroid carcinoma with apatinib
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
General Medicine
Reference21 articles.
1. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems;Kebebew;Cancer,2000
2. Medullary thyroid microcarcinoma: a population-level analysis of 310 patients;Kazaure;Cancer,2012
3. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population;Ahmed;Eur J Endocrinol,2011
4. The prognostic factors of medullary thyroid carcinoma;Shang;Chin Arch Otolaryngol Head Neck Surg,2003
5. Diagnostic approach, genetic screening and prognostic factors of medullary thyroid carcinoma;Corsello;Rays,2000
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Efficacy and Safety of Multikinase Inhibitors for Patients With Refractory Thyroid Cancer: Systematic Review and Network Meta-Analysis;The Journal of Clinical Endocrinology & Metabolism;2024-07-06
2. Role of heterocycles in inhibition of VEGFR-2 – a recent update (2019–2022);RSC Medicinal Chemistry;2024
3. Synthesis of novel nicotinic acid derivatives of potential antioxidant and anticancer activity;Archiv der Pharmazie;2023-10-04
4. The clinical efficacy of Apatinib plus Ba Zhen granules in the treatment of advanced unresectable differentiated thyroid cancer and their influence on immune factors;PAK J PHARM SCI;2023
5. Editorial: Apatinib and Anlotinib in the Treatment of Radioactive Iodine Refractory and Highly Invasive Thyroid Carcinoma;Journal of Clinical Medicine;2022-10-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3